Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(13):986; doi:10.1093/jnci/96.13.986
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

BRCA1 Discovery Led to Patent Debate, Genetic Screening

Sarah L. Zielinski

The first 10% of the full text of this article appears below.

This is part of an occasional series that recalls some of the stories reported 10 years ago in the News section of the Journal.

Although the announcement in 1994 that the BRCA1 gene had been isolated was greeted with much fanfare in the scientific community, it would be the debate about patents on the gene that would capture the spotlight in the following decade. Most recently, the European Patent Office (EPO) announced this May that it has revoked Myriad Genetics' European patent for their test that . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?